Details for Patent: 9,283,197

Which drugs does patent 9,283,197 protect, and when does it expire?

Patent 9,283,197 protects EPINEPHRINE and is included in one NDA.

Summary for Patent: 9,283,197

Patent landscape, scope, and claims:

Title:	More potent and less toxic formulations of epinephrine and methods of medical use
Abstract:	The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine.
Inventor(s):	Taneja; Jugal K. (Tampa, FL)
Assignee:
Application Number:	14/460,845
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,283,197
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 9,283,197

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bpi Labs	EPINEPHRINE	epinephrine	SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS	205029-001	Jul 29, 2014		RX	Yes	Yes			Y		Y	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
Bpi Labs	EPINEPHRINE	epinephrine	SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS	205029-001	Jul 29, 2014		RX	Yes	Yes			Y		Y	INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
Bpi Labs	EPINEPHRINE	epinephrine	SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS	205029-001	Jul 29, 2014		RX	Yes	Yes			Y		Y	INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY